Skip to main content

Epigenetic Biomarkers

Edited by Dawn DeMeo, James Flanagan, Harold Snieder, and Tomasz K. Wojdacz

New Content ItemClinical Epigenetics invites you to contribute a manuscript to our new thematic series, “Epigenetic Biomarkers”.

Epigenetic biomarkers have significantly contributed to improved understanding of the origins and progression of disease.  Moreover, increasing evidence shows that epigenetic biomarkers have potential for personalized medicine. However, routine use of epigenetic biomarkers in in-vitro diagnostics (IVD) is lagging behind the discoveries of new biomarkers. In this thematic series of Clinical Epigenetics, we discuss current progress in development of epigenetic biomarkers for clinical use in common complex diseases of ageing and welcome both original research and reviews.

The sections of the collection include:

  1. Types of epigenetic biomarkers and readiness for IVD use
    1. DNA methylation as biomarker
    2. Histone modification as biomarker
    3. Upcoming field of circulating free nucleosomes as biomarker
  2. Progress towards clinical use of biomarker

    1. Biomarkers of environmental exposures and causality of the biomarker

    2. Disease predisposition biomarkers

    3. Biomarkers used for disease detection

    4. Clinical disease prevention and management: predictive and prognostic

    5. Monitoring of chronic disease

  3. Single versus multiple biomarkers and risk scores
  4. Major stages of clinical validation of the biomarker
  5. Biomarker detection technologies suitable for IVD use and significance of bioinformatics
  6. Ethics and regulatory aspects of IVD epigenetic biomarkers

This collection of articles has not been sponsored and articles have undergone the journal’s standard peer-review process. Please find out more about our journal and its policies, here. Submission guidelines can be found here, and please submit to the series via our submission system (there will be a field for which you can indicate if you are submitting to this series).

All submissions should be made by December 1st, 2021.

  1. Current risk models for renal cell carcinoma (RCC) based on clinicopathological factors are sub-optimal in accurately identifying high-risk patients. Here, we perform a head-to-head comparison of previously pu...

    Authors: S. C. Joosten, S. N. O. Odeh, A. Koch, N. Buekers, M. J. B. Aarts, M. M. L. L. Baldewijns, L. Van Neste, S. van Kuijk, L. J. Schouten, P. A. van den Brandt, V. C. Tjan-Heijnen, M. van Engeland and K. M. Smits

    Citation: Clinical Epigenetics 2021 13:103

    Content type: Research

    Published on: